---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-105182"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2024-10-02T23:59:59+00:00"
generated_at: "2026-05-30T22:46:32.614168+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Liquidia expands L606 license to Europe/Japan; gets nebulizer rights; $3.5M upfront, up to $157.75M milestones

## Summary
- Expanded exclusive license to include Europe, Japan, and other key markets outside North America; $3.5M upfront payment.
- Up to $157.75M in additional milestone payments: $7.75M development + $150M commercial sales milestones outside North America.
- Obtained exclusive rights to Pharmosa's next-generation smart-technology nebulizers for use with L606.
- L606 pivotal study in PH-ILD expected to start later this year; positive EMA scientific advice received.
- Open-label safety study shows L606 tolerated up to 378 mcg twice daily; supports twice-daily dosing via breath-actuated nebulizer.

## SEC filing metadata
- accession: 0001104659-24-105182
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2024-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465924105182/0001104659-24-105182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465924105182/tm2425377d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-105182
- JSON: https://secwatch.observer/filing/0001104659-24-105182.json
- Plain text: https://secwatch.observer/filing/0001104659-24-105182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.